NYSEARCA:ARACX CIM Real Assets & Credit Fund (ARACX) Price, Holdings, & News → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free ARACX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AAssets Under Management$25.00Dividend YieldN/ANet Expense Ratio0.00% Stock AnalysisStock Analysis Get CIM Real Assets & Credit Fund alerts: Email Address About CIM Real Assets & Credit FundRead More Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read ARACX ETF News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive ARACX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CIM Real Assets & Credit Fund and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details Issuer Fund NameCIM Real Assets & Credit Fund - A Tax Classification Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:ARACX Inception Date1/1/2100 Fund ManagerN/A WebN/A PhoneN/AFund Focus Asset Class BenchmarkN/A Category Focus Development Level Region Number of Holdings0 Fund Statistics Assets Under Management$25.00 Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorN/A AdvisorN/A CustodianN/A DistributorN/A Transfer AgentN/A TrusteeN/A Lead Market MakerN/A Miscellaneous Outstanding SharesN/ABetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read CIM Real Assets & Credit Fund ExpensesTypeARACXNYSEARCA ETFsAll ETFsManagement Fee0.00%0.51%0.51%Other Expenses0.00%0.64%0.58%Total Expense0.00%0.74%0.70%Fee Waiver0.00%-0.68%-0.57%Net Expense0.00%0.58%0.58% CIM Real Assets & Credit Fund (ARACX)Full Holdings Details Similar ETFsAptus Large Cap Enhanced Yield ETFNYSEARCA:DUBSCambria Micro And Smallcap Shareholder Yield ETFNYSEARCA:MYLDCambria Tactical Yield ETFNYSEARCA:TYLDCIM Real Assets & Credit FundNYSEARCA:LRACXCIM Real Assets & Credit FundNYSEARCA:RACRX ARACX ETF - Frequently Asked Questions How do I buy shares of CIM Real Assets & Credit Fund? Shares of ARACX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:ARACX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CIM Real Assets & Credit Fund Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.